Nucleix Ltd., a Rehovot, Israel-based cancer detection and screening company, received €2.5m in funding.
The European H2020 / EIC pilot SME Instrument Programme, provided the funding.
The company intends to use the funds to accelerate the development of Lung EpiCheck™, a blood test for early detection of lung cancer.
Led by Opher Shapira, PhD, CEO, Nucleix develops, manufactures and markets innovative, non-invasive, molecular cancer diagnostic tests. The company is advancing Lung EpiCheck™, a screening diagnostic blood test for early detection of lung cancer. The test is based on proprietary molecular biomarker technology, which combines new biochemical assays and algorithms. The technology is based on identification and analysis of subtle changes in DNA methylation patterns, a tool for distinguishing between cancer and healthy cells and thus for detection of tumors in the body.
Investors in the company include OrbiMed and other investors.